Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of the Streptococcus mutans CRISPR-Cas systems in immunity and cell physiology.

Journal of bacteriology·2014
Same author

Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction.

Immunology today·2014
Same author

Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test.

Neuropharmacology·2012
Same author

Comments on measuring the contour of the cornea.

Applied optics·2010
Same author

The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.

Zoonoses and public health·2009
Same author

Transgenic overexpression of cardiac actin in the mouse heart suggests coregulation of cardiac, skeletal and vascular actin expression.

Transgenic research·2005
Same journal

Epidemiological and Environmental Risk Factors for Human Leptospirosis Cases in Buenos Aires Province, Argentina (2000-2016): An Ecological Study.

Zoonoses and public health·2026
Same journal

First Fatal Case of Adult Meningoencephalitis Caused by Pasteurella canis: An Autopsy Case Report.

Zoonoses and public health·2026
Same journal

Serological and Molecular Surveillance of Influenza A Virus in Dogs and Cats in Central Chile.

Zoonoses and public health·2026
Same journal

Whole Genome Characterization of Klebsiella Strains in European Hedgehogs and Human Nosocomial Settings Identified Shared Sequence Types, Antimicrobial Resistance Genes and Plasmids.

Zoonoses and public health·2026
Same journal

Mapping High-Rate Clusters of Animal Contact-Related Human Salmonella enterica Single-State Outbreaks in the United States, 2009-2022: A Spatial Epidemiological Approach to Inform Public Health Surveillance.

Zoonoses and public health·2026
Same journal

Barriers to Canine Rabies Vaccination in Nigeria: Implications for Rabies Elimination by 2030.

Zoonoses and public health·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
09:13

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Published on: November 1, 2011

Virus-like particle-based countermeasures against Rift Valley fever virus.

R Koukuntla1, R B Mandell, R Flick

  • 1BioProtection Systems, a wholly owned subsidiary of NewLink Genetics Corporation, Ames, IA, USA.

Zoonoses and Public Health
|September 11, 2012
PubMed
Summary
This summary is machine-generated.

A novel virus-like particle (VLP) vaccine candidate was developed to combat Rift Valley fever virus (RVFV). This VLP vaccine effectively protected animal models against lethal RVFV, demonstrating its potential for future human and livestock use.

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis
09:35

Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis

Published on: August 9, 2013

Related Experiment Videos

Last Updated: May 18, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
09:13

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy

Published on: November 1, 2011

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis
09:35

Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis

Published on: August 9, 2013

Area of Science:

  • Veterinary Virology
  • Vaccinology
  • Public Health

Background:

  • Rift Valley fever virus (RVFV) is an arbovirus posing significant risks to human and animal health.
  • Global travel and bioterrorism threats increase the potential for RVFV emergence in new regions.
  • Current lack of approved vaccines in the US necessitates the development of effective countermeasures.

Purpose of the Study:

  • To develop and evaluate a virus-like particle (VLP)-based vaccine candidate against RVFV.
  • To assess the immunogenicity and protective efficacy of RVF VLP vaccine candidates.

Main Methods:

  • Generation of a non-replicating chimeric RVF VLP vaccine.
  • Optimization of VLP production in insect and mammalian cells.
  • Evaluation of humoral and cellular immune responses in vaccinated animals.
  • Challenge studies with a lethal wild-type RVFV strain in protected animal models.

Main Results:

  • The RVF VLP vaccine candidate demonstrated protection in mice and rats against a lethal RVFV challenge.
  • VLP-based vaccine candidates successfully elicited both humoral and cellular immune responses.
  • Complete protection against lethal wild-type RVFV was observed in mice and rats post-vaccination.

Conclusions:

  • RVF VLP vaccine candidates represent a promising strategy for Rift Valley fever prevention.
  • The developed VLP vaccine elicits robust immune responses and provides complete protection in animal models.
  • Further development of this VLP vaccine could address the critical need for RVFV countermeasures.